These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
782 related articles for article (PubMed ID: 33428613)
21. Prevalence of BRCA1/BRCA2 mutations in a Brazilian population sample at-risk for hereditary breast cancer and characterization of its genetic ancestry. Fernandes GC; Michelli RA; Galvão HC; Paula AE; Pereira R; Andrade CE; Felicio PS; Souza CP; Mendes DR; Volc S; Berardinelli GN; Grasel RS; Sabato CS; Viana DV; Mauad EC; Scapulatempo-Neto C; Arun B; Reis RM; Palmero EI Oncotarget; 2016 Dec; 7(49):80465-80481. PubMed ID: 27741520 [TBL] [Abstract][Full Text] [Related]
22. BRCA1 and BRCA2 whole cDNA analysis in unsolved hereditary breast/ovarian cancer patients. Montalban G; Bonache S; Bach V; Gisbert-Beamud A; Tenés A; Moles-Fernández A; López-Fernández A; Carrasco E; Balmaña J; Diez O; Gutiérrez-Enríquez S Cancer Genet; 2021 Nov; 258-259():10-17. PubMed ID: 34237702 [TBL] [Abstract][Full Text] [Related]
23. Assessment of the functional impact of germline BRCA1/2 variants located in non-coding regions in families with breast and/or ovarian cancer predisposition. Dos Santos ES; Caputo SM; Castera L; Gendrot M; Briaux A; Breault M; Krieger S; Rogan PK; Mucaki EJ; Burke LJ; ; Bièche I; Houdayer C; Vaur D; Stoppa-Lyonnet D; Brown MA; Lallemand F; Rouleau E Breast Cancer Res Treat; 2018 Apr; 168(2):311-325. PubMed ID: 29236234 [TBL] [Abstract][Full Text] [Related]
25. Germ-line mutations in BRCA1 or BRCA2 in the normal breast are associated with altered expression of estrogen-responsive proteins and the predominance of progesterone receptor A. Mote PA; Leary JA; Avery KA; Sandelin K; Chenevix-Trench G; Kirk JA; Clarke CL; Genes Chromosomes Cancer; 2004 Mar; 39(3):236-48. PubMed ID: 14732925 [TBL] [Abstract][Full Text] [Related]
26. Prevalence and spectrum of BRCA germline variants in mainland Chinese familial breast and ovarian cancer patients. Kim YC; Zhao L; Zhang H; Huang Y; Cui J; Xiao F; Downs B; Wang SM Oncotarget; 2016 Feb; 7(8):9600-12. PubMed ID: 26848529 [TBL] [Abstract][Full Text] [Related]
27. Association between family history, mutation locations, and prevalence of BRCA1 or 2 mutations in ovarian cancer patients. Singer CF; Tan YY; Muhr D; Rappaport C; Gschwantler-Kaulich D; Grimm C; Polterauer S; Pfeiler G; Berger A; Tea MM Cancer Med; 2019 Apr; 8(4):1875-1881. PubMed ID: 30821131 [TBL] [Abstract][Full Text] [Related]
28. Germline variants profiling of BRCA1 and BRCA2 in Chinese Hakka breast and ovarian cancer patients. Zhang Y; Wu H; Yu Z; Li L; Zhang J; Liang X; Huang Q BMC Cancer; 2022 Aug; 22(1):842. PubMed ID: 35918668 [TBL] [Abstract][Full Text] [Related]
29. BRCA1 and BRCA2 Germline Mutation Analysis in Hereditary Breast/Ovarian Cancer Families from the Aures Region (Eastern Algeria): First Report. Mehemmai C; Cherbal F; Hamdi Y; Guedioura A; Benbrahim W; Bakour R; Abdelhak S Pathol Oncol Res; 2020 Apr; 26(2):715-726. PubMed ID: 30715675 [TBL] [Abstract][Full Text] [Related]
30. BRCA1 and BRCA2 mutations in males with familial breast and ovarian cancer syndrome. Results of a Spanish multicenter study. de Juan I; Palanca S; Domenech A; Feliubadaló L; Segura Á; Osorio A; Chirivella I; de la Hoya M; Sánchez AB; Infante M; Tena I; Díez O; Garcia-Casado Z; Vega A; Teulé À; Barroso A; Pérez P; Durán M; Carrasco E; Juan-Fita MJ; Murria R; Llop M; Barragan E; Izquierdo Á; Benítez J; Caldés T; Salas D; Bolufer P Fam Cancer; 2015 Dec; 14(4):505-13. PubMed ID: 26026974 [TBL] [Abstract][Full Text] [Related]
31. A systematic review on the frequency of BRCA promoter methylation in breast and ovarian carcinomas of BRCA germline mutation carriers: Mutually exclusive, or not? Vos S; van Diest PJ; Moelans CB Crit Rev Oncol Hematol; 2018 Jul; 127():29-41. PubMed ID: 29891109 [TBL] [Abstract][Full Text] [Related]
32. Identifying sequence variants contributing to hereditary breast and ovarian cancer in BRCA1 and BRCA2 negative breast and ovarian cancer patients. Jarhelle E; Riise Stensland HMF; Hansen GÅM; Skarsfjord S; Jonsrud C; Ingebrigtsen M; Strømsvik N; Van Ghelue M Sci Rep; 2019 Dec; 9(1):19986. PubMed ID: 31882575 [TBL] [Abstract][Full Text] [Related]
33. Analysis of the pathogenic variants of BRCA1 and BRCA2 using next-generation sequencing in women with familial breast cancer: a case-control study. Zayas-Villanueva OA; Campos-Acevedo LD; Lugo-Trampe JJ; Hernández-Barajas D; González-Guerrero JF; Noriega-Iriondo MF; Ramírez-Sánchez IA; Martínez-de-Villarreal LE BMC Cancer; 2019 Jul; 19(1):722. PubMed ID: 31331294 [TBL] [Abstract][Full Text] [Related]
34. Novel BRCA1 and BRCA2 germline mutations and assessment of mutation spectrum and prevalence in Italian breast and/or ovarian cancer families. Giannini G; Capalbo C; Ristori E; Ricevuto E; Sidoni T; Buffone A; Cortesi E; Marchetti P; Scambia G; Tomao S; Rinaldi C; Zani M; Ferraro S; Frati L; Screpanti I; Gulino A Breast Cancer Res Treat; 2006 Nov; 100(1):83-91. PubMed ID: 16847550 [TBL] [Abstract][Full Text] [Related]
35. Twenty Years of BRCA1 and BRCA2 Molecular Analysis at MMCI - Current Developments for the Classification of Variants. Machackova E; Claes K; Mikova M; Házová J; Sťahlová EH; Vasickova P; Trbusek M; Navrátilová M; Svoboda M; Foretová L Klin Onkol; 2019; 32(Supplementum2):51-71. PubMed ID: 31409081 [TBL] [Abstract][Full Text] [Related]
36. Comprehensive profiling of BRCA1 and BRCA2 variants in breast and ovarian cancer in Chinese patients. Gao X; Nan X; Liu Y; Liu R; Zang W; Shan G; Gai F; Zhang J; Li L; Cheng G; Song L Hum Mutat; 2020 Mar; 41(3):696-708. PubMed ID: 31825140 [TBL] [Abstract][Full Text] [Related]
37. Exon splicing analysis of intronic variants in multigene cancer panel testing for hereditary breast/ovarian cancer. Ryu JS; Lee HY; Cho EH; Yoon KA; Kim MK; Joo J; Lee ES; Kang HS; Lee S; Lee DO; Lim MC; Kong SY Cancer Sci; 2020 Oct; 111(10):3912-3925. PubMed ID: 32761968 [TBL] [Abstract][Full Text] [Related]
39. Prevalence of genetic susceptibility for breast and ovarian cancer in a non-cancer related study population: secondary germline findings from a Swiss single centre cohort. Kraemer D; Azzarello-Burri S; Steindl K; Boonsawat P; Zweier M; Dedes KJ; Joset P; Fink D; Rauch A Swiss Med Wkly; 2019 Aug; 149():w20092. PubMed ID: 31422574 [TBL] [Abstract][Full Text] [Related]
40. Evaluation of the contribution of germline variants in BRCA1 and BRCA2 to uveal and cutaneous melanoma. Johansson PA; Nathan V; Bourke LM; Palmer JM; Zhang T; Symmons J; Howlie M; Patch AM; Read J; Holland EA; Schmid H; Warrier S; Glasson W; Höiom V; Wadt K; Jönsson G; Olsson H; Ingvar C; Mann G; Brown KM; Hayward NK; Pritchard AL Melanoma Res; 2019 Oct; 29(5):483-490. PubMed ID: 31464824 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]